# NIH Reporter #1R42CA310337-01

Dual Acting Bone Defenders for Inhibiting Cancer Mediated Bone Destruction

**Recipient:** Not specified

**Award Amount:** $400,000.00
**Ceiling:** $400,000.00

**Awarded:** September 17, 2026

**Identifier:** 1R42CA310337-01

Award for developing a therapeutic to inhibit cancer-mediated bone destruction, including synthesis and toxicity studies, with a total amount of $400,000.

### Description

This project aims to develop a first-in-class therapeutic to inhibit bone destruction caused by cancer, with a focus on prostate, breast, and lung cancers. The project includes scale-up synthesis, toxicity studies, and IND submission.

[View original record](https://reporter.nih.gov/search/IgE1H2ioLUOz0qmA4MDg0Q/project-details/11314326)